Key result
This review addresses the most recent data concerning extended anticoagulation in VTE secondary prophylaxis, balancing the reduction of VTE recurrence risk against the risk of bleeding.
Why the study?
VTE recurrence risk often persists beyond 6 months of anticoagulation, raising questions about whether bleeding risks outweigh the benefits of extended treatment and which patients require prolonged therapy.
Does extended anticoagulation reduce VTE recurrence without unacceptable bleeding risk in patients with venous thromboembolism?
Does extended anticoagulation reduce VTE recurrence without unacceptable bleeding risk in patients with venous thromboembolism?
This review evaluates the recent data on the efficacy and safety of extended anticoagulation for secondary prophylaxis in patients with venous thromboembolism.
Answers are grounded in this paper and cite their sources.
Extended anticoagulation in VTE requires individualized bleeding-risk assessment; this review leaves open optimal duration and agent selection.
Most physicians understand venous thromboembolism (VTE) to be an acute and time-limited disease. However, pathophysiological and epidemiological data suggest that in most patients VTE recurrence risk is not resolved after the first 6 months of anticoagulation. Recurrence rates are high and potentially life-threatening. In these cases, it would make sense to prolong anticoagulation for an undetermined length of time. However, what about the bleeding rates, induced by prolonged anticoagulation? Would they not outweigh the benefit of reducing the VTE recurrent risk? How long should anticoagulation be continued, and should all patients suffering from VTE be provided with extended anticoagulation? This review will address the most recent data concerning extended anticoagulation in VTE secondary prophylaxis.
No takes yet. Share an insight, caveat, or question.
Fernandes et al. (2019) conducted a review in Venous thromboembolism (VTE). Extended anticoagulation was evaluated. This review addresses the most recent data concerning extended anticoagulation in VTE secondary prophylaxis, balancing the reduction of VTE recurrence risk against the risk of bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: